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The introduction of DNA microarrays and DNA sequencing technologies in medical genetics and diagnostics has been a challenge
that has signiﬁcantly transformed medical practice and patient management. Because of the great advancements in molecular
genetics and the development of simple laboratory technology to identify the mutations in the causative genes, also the diagnostic
approach to epilepsy has signiﬁcantly changed. However, the clinical use of molecular cytogenetics and high-throughput DNA
sequencing technologies, which are able to test an entire genome for genetic variants that are associated with the disease, is
preparing a further revolution in the near future. Molecular Karyotype and Next-Generation Sequencing have the potential to
identify causative genes or loci also in sporadic or non-familial epilepsy cases and may well represent the transition from a genetic
to a genomic approach to epilepsy.
1.Introduction
In the last decades a large number of gene discoveries have
changed our views of idiopathic and symptomatic epilepsy
[1]. Indeed, idiopathic epilepsy has the considerable genetic
advantage to be found very often in informative autosomal
dominant families that have been of great relevance to map
and to positional clone the causative gene, opening insight
into the biology and molecular pathology of this condition
[2, 3].
The search of epilepsy genes has allowed the identiﬁ-
cation of several genes in idiopathic generalized epilepsy
(Table 1), the vast majority of which are channelopathies [4,
5]oraﬀecttheactivityofexcitatoryorinhibitoryneurotrans-
mitters in central nervous system [6]. It is possible that the
dominantnatureofthesegenesduetothemultisubunitcom-
position of the molecules have greatly overestimated the role
of their mutations in the disease.
Other important insights came from the discoveries of
causativegenesofsyndromicepilepsy (Table 2)[7]andother
disorders where epilepsy is associated with encephalopathies
(Table 3)[ 8], mental retardation with brain malformation
(Table 4)[ 9, 10], other neurologic conditions including neu-
ronal migration disorders (Table 5)[ 11], and inborn errors
of metabolism (Tables 6 and 7)[ 12, 13]. Without any doubt,
these discoveries have been great advances in the ﬁeld; how-
ever, their impact on the management of epileptic patients
was limited because of the failure to collect signiﬁcant gen-
etic information from each patient to distinguish the large
number of genetic defects that can lead to the disease. There-
fore,genetictestingwaspossibleonlyforfeworselectedfam-
ily cases.
Technical improvements in human chromosomes recog-
nition and better deﬁnition of chromosome regions realized
by increasing the number of detectable chromosome bands
have provided higher resolution of normal and pathological
karyotype. It is today well established an association between
epilepticseizuresandchromosomeabnormalitiesrecognized
by high-resolution chromosome banding [14, 15]. However,
the type and the size of the chromosome defects are not
always easy to detect even by the highest-resolution cytoge-
netic techniques available for light microscopes.
The identiﬁcation of the speciﬁc genetic defect in a pa-
tient with epilepsy may clarify the diagnosis (diagnostic test-
ing), suggest the prognosis, assist with treatment and mana-
gement (e.g., the use of a ketogenic diet in glucose transpor-
ter type 1 deﬁciency syndrome or the avoidance of lamotrig-
ine, phenytoin, and carbamazepine in Dravet syndrome),
elucidate the risk of a disease in family members and fu-
ture children, and save the patient from further diagnostic
evaluation and potentially invasive testing.2 Neurology Research International
Table 1: Disease genes identiﬁed in generalized myoclonic epilepsy, febrile seizures, absences (37 genes).
Gene Symbol Gene name and description
ALDH7A1 Aldehyde dehydrogenase 7 family, member A1
BRD2 Bromodomain containing 2
CACNA1A Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit
CACNA1H Calcium channel, voltage-dependent, T type, alpha 1H subunit
CACNB4 Calcium channel, voltage-dependent, beta 4 subunit
CASR Calcium-sensing receptor
CHRNA2 Cholinergic receptor, nicotinic, alpha 2 (neuronal)
CHRNA4 Cholinergic receptor, nicotinic, alpha 4
CHRNB2 Cholinergic receptor, nicotinic, beta 2 (neuronal)
CLCN2 Chloride channel 2
CSTB Cystatin B (steﬁn B)
EFHC1 EF-hand domain (C-terminal) containing 1
EPM2A Epilepsy, progressive myoclonus type 2A, Lafora disease (laforin)
GABRA1 Gamma-aminobutyric acid (GABA) A receptor, alpha 1
GABRB3 Gamma-aminobutyric acid (GABA) A receptor, beta 3
GABRD Gamma-aminobutyric acid (GABA) A receptor, delta
GABRG2 Gamma-aminobutyric acid (GABA) A receptor, gamma 2
GPR98 G protein-coupled receptor 98
GRIN2A Glutamate receptor, ionotropic, N-methyl D-aspartate 2A
GRIN2B Glutamate receptor, ionotropic, N-methyl D-aspartate 2B
KCNMA1 Potassium large conductance calcium-activated channel, subfamily M, alpha member 1
KCNQ2 Potassium voltage-gated channel, KQT-like subfamily, member 2
KCNQ3 Potassium voltage-gated channel, KQT-like subfamily, member 3
KCTD7 Potassium channel tetramerisation domain containing 7
MBD5 Methyl-CpG-binding domain protein 5
ME2 Malic enzyme 2, NAD(+)-dependent, mitochondrial
NHLRC1 NHL repeat containing 1
PCDH19 Protocadherin 19
PRICKLE1 Prickle homolog 1 (Drosophila)
PRICKLE2 Prickle homolog 2 (Drosophila)
SCARB2 Scavenger receptor class B, member 2
SCN1A Sodium channel, voltage-gated, type I, alpha subunit
SCN1B Sodium channel, voltage-gated, type I, beta subunit
SCN2A Sodium channel, voltage-gated, type II, alpha subunit
SCN9A Sodium channel, voltage-gated, type IX, alpha subunit
SLC2A1 Solute carrier family 2 (facilitated glucose transporter), member 1
TBC1D24 TBC1 domain family, member 24
In asymptomatic subjects with increased risk of seizures
because of a family history, genetic test may predict onset of
epilepsy (predictive testing) [16, 17]. Despite such potential
beneﬁts, genetic testing has also potential harms, such as
its ethical, legal, and social implications, and the potential
for stigma, distress, adverse labeling, and nonconﬁdentiality
that exists in the setting of inadequate safeguards against
discrimination [18]. Considering that our understanding of
the epidemiology and clinical utility of genetic testing in the
epilepsies is incomplete, the assessmentof these potential be-
neﬁts and harms is particularly complex and is closely linked
to the clinical scenario.
TheInternationalLeagueAgainstEpilepsy(ILAE)Genet-
ic Commission presented a tool in the approach to speciﬁc
tests for epilepsy [16]. According to ILAE report, the diag-
nostic genetic testing is “very useful” in individual aﬀected
by early-onset spasms, X-linked infantile spasms, Dravet and
related syndromes, Ohtahara syndrome, epilepsy and mental
retardation limited to females, early-onset absence epilepsy,
autosomal dominant nocturnal frontal lobe epilepsy, and
epilepsy with paroxysmal exercise-induced dyskinesia; the
predictivetestingis“veryuseful”inunaﬀectedrelativesofin-
dividuals aﬀected by Dravet syndrome and epilepsy and
mental retardation limited to females [16]. ConsideringNeurology Research International 3
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Table 3: Disease genes identiﬁed in epileptic encephalopathies (30 genes).
Gene symbol Gene Name and Description Diseases
ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9 Early infantile epileptic encephalopathy
ARX Aristaless related homeobox Early infantile epileptic encephalopathy
CDKL5 Cyclin-dependent kinase-like 5 Early infantile epileptic encephalopathy
CNTNAP2 Contactin associated protein-like 2 Pitt Hopkins syndrome
FOXG1 Forkhead box G1 Rett syndrome
GABRG2 Gamma-aminobutyric acid (GABA) A receptor, gamma 2 Early infantile epileptic encephalopathy
GRIN2A Glutamate receptor, ionotropic, N-methyl D-aspartate 2A Early infantile epileptic encephalopathy
GRIN2B Glutamate receptor, ionotropic, N-methyl D-aspartate 2B Early infantile epileptic encephalopathy
MAPK10 Mitogen-activated protein kinase 10 Lennox Gastaut syndrome
MECP2 Methyl CpG binding protein 2 Rett syndrome
NRXN1 Neurexin 1 Pitt Hopkins Syndrome
PCDH19 Protocadherin 19 Early infantile epileptic encephalopathy
PNKP Polynucleotide kinase 3’-phosphatase Early infantile epileptic encephalopathy
RNASEH2A Ribonuclease H2, subunit A Aicardi-Goutieres syndrome
RNASEH2B Ribonuclease H2, subunit B Aicardi-Goutieres syndrome
RNASEH2C Ribonuclease H2, subunit C Aicardi-Goutieres syndrome
SAMHD1 SAM domain and HD domain 1 Aicardi-Goutieres syndrome
SCN1A Sodium channel, voltage-gated, type I, alpha subunit Early infantile epileptic encephalopathy
SCN1B Sodium channel, voltage-gated, type I, beta subunit Early Infantile epileptic encephalopathy
SCN2A Sodium channel, voltage-gated, type II, alpha subunit Early infantile epileptic Encephalopathy
SCN9A Sodium channel, voltage-gated, type IX, alpha subunit Early infantile epileptic encephalopathy
SLC2A1 Solute carrier family 2 (facilitated glucose transporter), member 1 GLUT1 deﬁciency syndrome
SLC25A22 Solute carrier family 25 (mitochondrial carrier: glutamate), member 22 Early infantile epileptic encephalopathy
SLC9A6 Solute carrier family 9 (sodium/hydrogen exchanger), member 6 Angelman syndrome
SPTAN1 Spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) Early infantile epileptic encephalopathy
STXBP1 Syntaxin binding protein 1 Early infantile epileptic encephalopathy
TCF4 Transcription factor 4 Pitt Hopkins syndrome
TREX1 Three prime repair exonuclease 1 Aicardi-Goutieres syndrome
UBE3A Ubiquitin protein ligase E3A Angelman syndrome
ZEB2 Zinc ﬁnger E-box binding homeobox 2 Mowat-Wilson syndrome
the potential harms, genetic testing should always be perfor-
medwiththepatient’sconsentorparentalconsentinthecase
of minors. A team approach, including a genetic counselor, a
psychologist, and a social worker, is recommended through-
out the process of evaluation.
In the last years a number of new molecular genetic tech-
nologies became available and they promise to change gen-
etic testing for epilepsy, allowing to extend genetic analysis
also to sporadic or nonfamilial cases. Two are the major new
technologies that can aﬀect the management of epileptic pa-
tients: Oligonucleotide Arrays Comparative Genomic Hybri-
dization (Array-CGH) and Next-Generation Sequencing
(NGS).
2.MolecularKaryotype
Duringthelast50yearscytogeneticshasevolvedfromsimple
chromosome counting or banded chromosome morpholog-
ical identiﬁcation under light microscope to a molecular
approach where chromosomes are analyzed through sophis-
ticated computer system for their ability to hybridize to spe-
ciﬁc oligonucleotides spanning the entire genome [19]. Ar-
ray-CGH is nowadays a basic diagnostic tool for clinical dia-
gnosis of several types of developmental delays [20], intellec-
tual disabilities [21, 22], and congenital abnormalities [23].
Epilepsy is also enjoying several advantages from the use
of this technology that signiﬁcantly improves diagnostic re-
solution of classic cytogenetics [24, 25].
Chromosomes did not become individually identiﬁable
before the discovery that several procedures could create re-
producible, permanent, and speciﬁc banding patterns [26,
27]. This was fundamental for gene mapping and positional
cloning of disease genes and also revealed a large number of
rare and subtle pathological conditions that disturbed the
normal band patterning of chromosomes. The improve-
ments of high-resolution banding techniques allowed the id-
entiﬁcation of several subtle chromosomal abnormalities as-
sociated with epilepsy [14, 15]. The possibility to study6 Neurology Research International
Table 4: Epilepsy with mental retardation and brain malformations.
Gene symbol Name Disease
(a) Mental retardation (25 genes)
ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9 Early infantile epileptic encephalopathy
ARX Aristaless related homeobox Early infantile epileptic encephalopathy
ATP6AP2 ATPase, H+ transporting, lysosomal accessory protein 2 Epilepsy with XLMR∗
ATRX Alpha thalassemia/mental retardation syndrome X-linked Epilepsy with XLMR∗
CASK Calcium/calmodulin-dependent serine protein kinase (MAGUK family) Mental retardation and microcephaly
CDKL5 Cyclin-dependent kinase-like 5 Early infantile epileptic encephalopathy
CUL4B Cullin 4B Epilepsy with XLMR∗
CXORF5 Oral-facial-digital syndrome 1 Simpson-Golabi-Behmel syndrome
DCX Doublecortin Lissencephaly
FGD1 FYVE, RhoGEF and PH domain containing 1 Aarskog-Scott syndrome
GPC3 Glypican 3 Simpson-Golabi-Behmel syndrome
GRIA3 Glutamate receptor, ionotrophic, AMPA 3 Epilepsy with XLMR∗
HSD17B10 Hydroxysteroid (17-beta) dehydrogenase 10 Epilepsy with XLMR∗
JARID1C Lysine (K)-speciﬁc demethylase 5C Epilepsy with XLMR∗
OPHN1 Oligophrenin 1 Epilepsy with XLMR∗
PAK3 P21 protein (Cdc42/Rac)-activated kinase 3 Epilepsy with XLMR∗
PHF6 PHD ﬁnger protein 6 Borjeson Forssmann Lehmann syndrome
PLP1 Proteolipid protein 1 Pelizaeus-Merzbacher disease
PQBP1 Polyglutamine binding protein 1 Epilepsy with XLMR∗
RAB39B RAB39B, member RAS oncogene family Epilepsy with XLMR∗
SLC9A6 Solute carrier family 9 (sodium/hydrogen exchanger), member 6 Angelman-Like syndrome
SMC1A Structural maintenance of chromosomes 1A Cornelia De Lange syndrome
SMS Spermine synthase Epilepsy with XLMR∗
SRPX2 Sushi-repeat containing protein, X-linked 2 Rolandic epilepsy
SYP Synaptophysin Epilepsy with XLMR∗
∗XLMR: X-linked mental retardation
(b) Joubert syndrome (10 genes)
AHI1 Abelson helper integration site 1 Joubert syndrome
ARL13B ADP-ribosylation factor-like 13B Joubert syndrome
CC2D2A Coiled-coil and C2 domain containing 2A Joubert syndrome
CEP290 Centrosomal protein 290kDa Joubert syndrome
CXORF5 Oral-facial-digital syndrome 1 Joubert syndrome
INPP5E Inositol polyphosphate-5-phosphatase, 72kDa Joubert syndrome
NPHP1 Nephronophthisis 1 (juvenile) Joubert syndrome
RPGRIP1L Retinitis pigmentosa GTPase regulator interacting protein 1 like Joubert syndrome
TMEM67 Transmembrane protein 67 Joubert syndrome
TMEM216 Transmembrane protein 216 Joubert syndrome
(c) Lissencephaly and polymicrogyria (18 genes)
COL18A1 Collagen, type XVIII, alpha 1 Polymicrogyria
CPT2 Carnitine palmitoyltransferase 2 Polymicrogyria
DCX Doublecortin Lissencephaly
EOMES Eomesodermin Polymicrogyria
FGFR3 Fibroblast growth factor receptor 3 Polymicrogyria
FLNA Filamin A, alpha Periventricular heterotopia
GPR56 G protein-coupled receptor 56 PolymicrogyriaNeurology Research International 7
Table 4: Continued.
Gene symbol Name Disease
PAFAH1B1 Platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 (45kDa) Lissencephaly
PAX6 Paired box 6 Polymicrogyria
PEX7 Peroxisomal biogenesis factor 7 Polymicrogyria
RAB3GAP1 RAB3 GTPase activating protein subunit 1 (catalytic) Warburg microsyndrome
RELN Reelin Lissencephaly
SNAP29 Synaptosomal-associated protein, 29kDa Cerebral dysgenesis
SRPX2 Sushi-repeat containing protein, X-linked 2 Rolandic epilepsy
TUBA1A Tubulin, alpha 1a Lissencephaly
TUBA8 Tubulin, alpha 8 Polymicrogyria
TUBB2B Tubulin, beta 2B Polymicrogyria
VDAC1 Voltage-dependent anion channel 1 Polymicrogyria
(d) Severe microcephaly and pontocerebellar hypoplasia (22 genes)
ASPM Asp (abnormal spindle) homolog, microcephaly associated (Drosophila) Microcephaly
ATR Ataxia telangiectasia and Rad3 related Microcephaly
BUB1B Budding uninhibited by benzimidazoles 1 homolog beta (yeast) Microcephaly
CASK Calcium/calmodulin-dependent serine protein kinase (MAGUK family) Microcephaly
CDK5RAP2
[Microcephaly] CDK5 regulatory subunit associated protein 2 Microcephaly
CENPJ Centromere protein J Microcephaly
CEP152 Centrosomal protein 152kDa Microcephaly
LIG4 Ligase IV, DNA, ATP-dependent Microcephaly
MCPH1 Microcephalin 1 Microcephaly
MED17 Mediator complex subunit 17 Microcephaly
NHEJ1 Nonhomologous end-joining factor 1 Microcephaly
PCNT Pericentrin Microcephalic osteodysplastic Dwarﬁsm
PNKP Polynucleotide kinase 3
 -phosphatase Microcephaly
PQBP1 Polyglutamine binding protein 1 X-linked mental retardation
RARS2 Arginyl-tRNA synthetase 2, mitochondrial Pontocerebellar hypoplasia
SLC25A19 Solute carrier family 25 (mitochondrial thiamine pyrophosphate carrier),
member 19 Microcephaly
STIL SCL/TAL1 interrupting locus Microcephaly
TSEN2 tRNA splicing endonuclease 2 homolog (S. cerevisiae) Pontocerebellar hypoplasia
TSEN34
[Pontocerebellar
Hypoplasia]
tRNA splicing endonuclease 34 homolog (S. cerevisiae) Pontocerebellar hypoplasia
TSEN54
[Pontocerebellar
Hypoplasia]
tRNA splicing endonuclease 54 homolog (S. cerevisiae) Pontocerebellar hypoplasia
VRK1 Vaccinia related kinase 1 Pontocerebellar hypoplasia
WDR62 WD repeat domain 62 Microcephaly, cortical malformations
a n dm e n t a lr e t a r d a t i o n
(e) Walker-Warburg syndrome (WWS) or muscle, eye and brain disease (6 genes) anomalies type A2 (MDDGA2)
FKRP Fukutin-related protein Walker-Warburg syndrome
FKTN Fukutin Walker-Warburg syndrome
LARGE Like-glycosyltransferase Walker-Warburg syndrome
POMGNT1 Protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase Walker-Warburg syndrome
POMT1 Protein-O-mannosyltransferase 1 Walker-Warburg syndrome
POMT2 Protein-O-mannosyltransferase 2 Walker-Warburg Syndrome8 Neurology Research International
Table 4: Continued.
Gene symbol Name Disease
(f) Holoprosencephaly (HPE) (8 genes)
FGF8 Fibroblast growth factor 8 (androgen-induced) Holoprosencephaly
GLI2 GLI family zinc ﬁnger 2 Holoprosencephaly 9
GLI3 GLI family zinc ﬁnger 3 Greig cephalopolysyndactyly syndrome
PTCH1 patched 1 Holoprosencephaly 7
SHH Sonic Hedgehog Holoprosencephaly 3
SIX3 SIX homeobox 3 Holoprosencephaly 2
TGIF1 TGFB-induced factor homeobox 1 Holoprosencephaly 4
ZIC2 Zic family member 2 Holoprosencephaly 5
these chromosomes regions with speciﬁc hybridization DNA
probes through ﬂuorescence in situ hybridization (FISH)
greatlyimprovedsensitivitytodetectsmallchromosomalab-
errations in speciﬁc regions [28].
Today molecular karyotyping is rapidly replacing con-
ventional cytogenetics and FISH. This name refers to the an-
alysis of all chromosomes using hybridization to standard
DNA sequences arranged on a “chip” rather than micro-
scope observation. The technological development of this
approachallowsnowclinicianstoevaluatetheentiregenome
for copy number variants (CNVs, duplications, deletions) in
a single test. The high resolution of this approach is however
limited by the diﬃculty to identify balanced chromosome
translocations or inversions, even if this powerful technique
recognizes in many of them microdeletions or cryptic ano-
malies at the chromosomal breakpoints. Detection of dele-
tions or duplications is based on the comparison of two
genomes (Figure 1). Labelled patient DNA is cohybridized
with control DNA to an array spotted with oligonucleotide
DNA probes spanning the entire genome at critical intervals.
The distance between these oligonucleotide sequences in the
genome marks the resolution of the technique and can be as
low as 1000bp. The intensity of the signal from patient and
control are then read and normalized by an electronic scan-
ning device coupled with a software that generates a graphic
plot of intensities for each probe.
A search of Online Mendelian Inheritance in Man
(OMIM)clinicalsynopsiswiththeterm“seizure”revealsthat
there are at least 754 mendelian disorders in which epilepsy
is or can be part of the clinical condition, but not the main
feature. Many of these disorders can be associated with DNA
sequence mutations or subtle chromosomal anomalies that
can be conveniently detected by array-CGH. Some will be
private or sporadic cases and others will be familial. With the
widespread use of CGH in both circumstances, many more
genetic events will be reported in patients and the genetic
aetiology will be recognized making possible over the time
to saturate the genome with all possible loci and events that
have an epileptogenic role.
3. Next-GenerationSequencing
Fromthepublicationofthedraftofhumangenomesequence
in Nature, on 15th February 2001 issue, our view and
Array-CGH
Patient’s DNA Reference DNA
Hybridization
Oligonucleotide array
Loss of DNA
(deletion)
Gain of DNA
(CNV)
Hybridization
Oligonucleotide array
Figure 1
knowledge of human genome has considerably changed [29]
and the technologies to sequence DNA are today of com-
mon use in diagnostic practice and much cheaper. Chain
termination or Sanger’s method [30] was largely used for
the Human Genome Project and has dominated the past
decades. The logic of this technology was to create by syn-
thesis a population of DNA fragments of diﬀerent size each
one terminated at all possible positions by one of the four
labelled dideoxynucleotides (ddNTPs) terminators. Separa-
tion of these fragments by polyacrylamide gel or capillary
electrophoresis allowed the reading of the sequence through
the ﬁrst developed sequencing machines that could distin-
guish the ﬂuorescence emitted by the blocking ddNTP [31].
Therefore,theseareconsideredthe“ﬁrstgeneration”ofDNA
sequencing technologies.
The need to reduce the cost of large sequencing projects
has stimulated the development of a variety of cheaper seq-
uencing technologies that are generally called “Next-Gen-
eration Sequencing” (NGS) [32, 33] .T h eﬁ n a lg o a lo ft h i s
new ﬁeld is to reduce the cost of human genome sequencing
till or lower than $1,000 per genome to make it availableNeurology Research International 9
Table 5: Epilepsy with other neurological problems.
Gene symbol Name Disease
(a) Leukodystrophies (20 genes)
ARSA Arylsulfatase A Leukodystrophy metachromatic (MLD)
ASPA Aspartoacylase Canavan disease
EIF2B1 Eukaryotic translation initiation factor 2B, subunit 1 alpha, 26kDa Leukodystrophy
EIF2B2 Eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa Leukodystrophy
EIF2B3 Eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa Leukodystrophy
EIF2B4 Eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa Leukodystrophy
EIF2B5 Eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa Leukodystrophy
GALC Galactosylceramidase Leukodystrophy globoid cell (GLD)
GFAP Glial ﬁbrillary acidic protein Alexander disease
MLC1 Megalencephalic leukoencephalopathy with subcortical cysts 1 Megalencephalic leukoencephalopathy
NOTCH3 Notch3 CADASIL
PLP1 Proteolipid protein 1 Leukodystrophy hypomyelinating type 1 (HLD1)
PSAP Prosaposin Leukodystrophy metachromatic
RNASEH2A Ribonuclease H2, subunit A Aicardi-Goutieres syndrome type 4 (AGS4)
RNASEH2B Ribonuclease H2, subunit B Aicardi-Goutieres syndrome type 2 (AGS2)
RNASEH2C Ribonuclease H2, subunit C Aicardi-Goutieres syndrome type 3 (AGS3
SAMHD1 SAM domain and HD domain 1 Aicardi-Goutieres syndrome type 5 (AGS5)
SDHA Succinate dehydrogenase complex, subunit A, ﬂavoprotein (Fp) Leigh syndrome
SUMF1 Sulfatase modifying factor 1 Multiple sulfatase deﬁciency (MSD)
TREX1 Three prime repair exonuclease 1 Aicardi-Goutieres syndrome type 1 (AGS1)
(b) Migraine (6 genes)
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 polypeptide Migraine familial hemiplegic type 2 (FHM2)
CACNA1A Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit Spinocerebellar ataxia type 6 (SCA6)
NOTCH3 Notch 3 CADASIL
POLG Polymerase (DNA directed), gamma Progressive external ophthalmoplegia
SCN1A Sodium channel, voltage-gated, type I, alpha subunit Migraine familial hemiplegic type 3 (FHM3)
SLC2A1 Solute carrier family 2 (facilitated glucose transporter), member 1 GLUT1 deﬁciency type 1
(GLUT1DS1) syndrome
(c) Disorders of Ras-MAPK pathway with epilepsy (13 genes)
BRAF V-raf murine sarcoma viral oncogene homolog B1 Cardiofaciocutaneous (CFC ) syndrome
CBL Cas-Br-M (murine) ecotropic retroviral transforming sequence Noonan syndrome-like disorder (NSL)
HRAS V-Ha-ras Harvey rat sarcoma viral oncogene homolog Faciocutaneoskeletal (FCSS) syndrome
KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog Noonan type 3 (NS3) syndrome
MAP2K1 Mitogen-activated protein kinase kinase 1 cardiofaciocutaneous (CFC) syndrome
MAP2K2 Mitogen-activated protein kinase kinase 2 cardiofaciocutaneous (CFC) syndrome
NF1 Neuroﬁbromin 1 Neuroﬁbromatosis type 1
NRAS Neuroblastoma RAS viral (v-ras) oncogene homolog Noonan type 6 (NS6) syndrome
PTPN11 Protein tyrosine phosphatase, non-receptor type 11 LEOPARD type 1 (LEOPARD1) syndrome
RAF1 V-raf-1 murine leukemia viral oncogene homolog 1 Noonan type 5 (NS5) syndrome
SHOC2 Soc-2 suppressor of clear homolog (C. elegans) Noonan syndrome-like with loose anagen hair
SOS1 Son of sevenless homolog 1 (Drosophila) Noonan type 4 (NS4) syndrome
SPRED1 Sprouty-related, EVH1 domain containing 1 Neuroﬁbromatosis type 1-like syndrome
(d) Hyperekplexia (5 genes)
ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9 Hyperekplexia with epilepsy
GLRA1 Glycine receptor, alpha 1 Hyperekplexia with epilepsy
GLRB Glycine receptor, beta Hyperekplexia with epilepsy10 Neurology Research International
Table 5: Continued.
Gene symbol Name Disease
GPHN Gephyrin Hyperekplexia with epilepsy
SLC6A5 solute carrier family 6 (neurotransmitter, transporter, glycine),
member 5 Hyperekplexia with epilepsy
(e) Neuronal migration disorders (31 genes)
ARFGEF2 ADP-ribosylation factor guanine nucleotide-exchange factor 2
(brefeldin A-inhibited) Microcephaly
ARX Aristaless-related homeobox Early infantile epileptic encephalopathy
COL18A1 Collagen, type XVIII, alpha 1 Polymicrogyria
COL4A1 Collagen, type IV, alpha 1 Porencephaly
CPT2 Carnitine palmitoyltransferase 2 Polymicrogyria
DCX Doublecortin Lissencephaly
EMX2 Empty spiracles homeobox 2 Schizencephaly
EOMES Eomesodermin Polymicrogyria
FGFR3 Fibroblast growth factor receptor 3 Polymicrogyria
FKRP Fukutin related protein Walker-Warburg syndrome
FKTN Fukutin Walker-Warburg syndrome
FLNA Filamin A, alpha Periventricular heterotopia
GPR56 G protein-coupled receptor 56 Polymicrogyria
LAMA2 Laminin, alpha2 Merosin deﬁciency
LARGE Like-glycosyltransferase Walker-Warburg syndrome
PAFAH1B1 Platelet-activating factor acetylhydrolase 1b, regulatory subunit 1
(45kDa) Lissencephaly
PAX6 Paired box 6 Polymicrogyria
PEX7 Peroxisomal biogenesis factor 7 Polymicrogyria
POMGNT1 Protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase Walker-Warburg syndrome
POMT1 Protein O-mannosyltransferase 1 Walker-Warburg syndrome
POMT2 Protein O-mannosyltransferase 2 Walker-Warburg syndrome
PQBP1 Polyglutamine binding protein 1 X-linked mental retardation
RAB3GAP RAB3 GTPase activating protein subunit 1 (catalytic) Warburg microsyndrome
RELN Reelin Lissencephaly
SNAP29 Synaptosomal-associated protein, 29kDa Cerebral dysgenesis
SRPX2 Sushi-repeat containing protein, X-linked 2 Rolandic epilepsy
TUBA1A Tubulin, alpha 1a Lissencephaly
TUBA8 Tubulin, alpha 8 Polymicrogyria
TUBB2B Voltage-dependent anion channel 1 Polymicrogyria
VDAC1 Voltage-dependent anion channel 1 Polymicrogyria
WDR62 WD repeat domain 62 Microcephaly, cortical malfor, mental
retardatation
for common medical practice and diagnostic use [34]. The
development of further third-generation sequencing tech-
nologies should make possible to sequence single DNA mol-
e c u l e si nr e a lt i m ew i t hac o s tt h a ti ti sp r o j e c t e dt ob ev e r y
close to the goal [35].
Thed ev elo p me nto fNGSplatf o rmswasamajo rp r ogr ess
in the technology because, diﬀerently from Sanger method,
rather than producing about one thousand nucleotides for
run, they are able to produce orders of magnitude more seq-
uence data using massive parallel process, resulting in sub-
stantial increase of data at a lower cost per nucleotide [36,
37].
Severalcommercialplatformsaretodayavailable,includ-
ing Roche/454 [38], Illumina/Solexa and Life Technolo-
gies/SOLiD (Table 8(a)). In very general terms these plat-
forms follow similar process that includes: (a) template
preparation by breaking large DNA macromolecule to gen-
erate short fragment libraries with platform-speciﬁc synthe-
tic DNA adapters at the fragment ends, (b) massive and pa-
rallelclonalampliﬁcationofindividualDNAfragmentmole-
cules on glass slide or microbeads by PCR [39] to generate
as u ﬃcient copy number of the labelled fragment to be de-
tected by the machine optical system, and (c) sequencing by
several cycles of extensions that are repeated and detectedNeurology Research International 11
Table 6: Inherited errors of metabolism with epilepsy (49 genes).
Gene symbol Defective enzyme name Disease
ABCC8 ATP-binding cassette, subfamily C (CFTR/MRP), member 8 Hypoglcemia
ACY1 Aminoacylase1 Aminoacylase1 deﬁciency
ADSL Adenylosuccinate lyase Adenylosuccinase deﬁciency
AGA Aspartylglucosaminidase Aspartylglucosaminuria
ALDH4A1 Aldehyde dehydrogenase 4 family, member A1 Hyperprolinemia
ALDH5A1 Aldehyde dehydrogenase 5 family, member A1 Succinic Semialdehyde dehydrogenase
deﬁciency
ALDH7A1 Aldehyde dehydrogenase 7 family, member A1 Pyridoxine deﬁciency
ARG1 Liver arginase Argininemia
ARSA Arylsulfatase A Metachromatic leukoodystrophy
ASPA Aspartoacylase Canavan disease
ATIC 5-aminoimidazole-4-carboxamide ribonucleotide (AICAr)
formyltransferase/IMP cyclohydrolase
AICAr transformylase/IMP
cyclohydrolase deﬁciency (ATIC
Deﬁciency)
BTD Biotinidase Biotinidase deﬁciency
CPT2 Carnitine palmitoyltransferase 2 Carnitine palmitoyltransferase II
deﬁciency
CTSA Cathepsin A Galactosialidosis
DPYD Dihydropyrimidine dehydrogenase Dihydropyrimidine dehydrogenase
deﬁciency
ETFA Electron-transfer-ﬂavoprotein, alpha polypeptide Glutaraciduria
ETFB Electron-transfer-ﬂavoprotein, beta polypeptide Glutaraciduria
ETFDH Electron-transferring-ﬂavoprotein dehydrogenase Glutaraciduria
FH Fumarate hydratase Fumarase deﬁciency
FOLR1 Folate receptor 1 (adult) Cerebral folate transport deﬁciency
FUCA1 Fucosidase, alpha-L- 1, tissue Fucosidosis
GALC Galactosylceramidase Krabbe disease
GAMT Guanidinoacetate N-methyltransferase Guanidinoacetate N-methyltransferase
deﬁciency
GCDH Glutaryl-CoA dehydrogenase Glutaraciduria
GCSH Glycine cleavage system protein H (aminomethyl carrier) Glycine encephalopathy
GCST Glycine cleavage system protein T (aminomethyltransferase) Glycine encephalopathy
GLB1 Galactosidase, beta 1 Gangliosidosis
GLDC Glycine dehydrogenase (decarboxylating) Glycine encephalopathy
GNE Glucosamine
(UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase Sialuria
HEXA Hexosaminidase A (alpha polypeptide) Gangliosidosis
HEXB Hexosaminidase B (beta polypeptide) Gangliosidosis
HPD 4-Hydroxyphenylpyruvate dioxygenase Tyrosinemia
L2HGDH L-2-Hydroxyglutarate dehydrogenase L-2-Hydroxyglutaric aciduria
LAMA2 Laminin, alpha 2 Muscular dystrophy
MOCS1 Molybdenum cofactor synthesis 1 Molybdene cofactor deﬁciency
MOCS2 Molybdenum cofactor synthesis 2 Molybdene cofactor deﬁciency
NEU1 Sialidase 1 (lysosomal sialidase) Neuraminidase deﬁciency
NPC1 Niemann-Pick disease, type C1 Niemann-Pick disease
NPC2 Niemann-Pick disease, type C2 Niemann-Pick disease
PGK1 Phosphoglycerate kinase 1 GAMT deﬁciency
PRODH Proline dehydrogenase (oxidase) 1 Hyperprolinemia
PSAP Prosaposin Krabbe disease
QDPR Quinoid dihydropteridine reductase Hyperphenylalaninemia12 Neurology Research International
Table 6: Continued.
Gene symbol Defective enzyme name Disease
SLC17A5 Solute carrier family 17 (anion/sugar transporter), member 5 Sialuria
SLC25A15 Solute carrier family 25 (mitochondrial carrier; ornithine
transporter) member 15 Ornithine translocase deﬁciency
SLC46A1 Solute carrier family 46 (folate transporter), member 1 Folate malabsorption
SMPD1 Sphingomyelin phosphodiesterase 1, acid lysosomal Niemann pick disease
SUMF1 Sulfatase modifying factor 1 Sulfatidosis
SUOX Sulﬁte oxidase Sulﬁtoxidasis
automatically to create short reads [40]. The data of these
reads are then collected by the device, and the alignment
of the short reads with speciﬁc software allows to rebuild
the initial template sequence. Helicos and Paciﬁc Biosystem
platforms (Table 8(b)) are substantially diﬀerent because
they use a more advanced laser-based detection system that
does not require massive parallel ampliﬁcation with the con-
siderable advantages to simplify preparation process, to
eliminate PCR-induced bias and errors, and to make easy
data collection. Ion Torrent developed an entirely new ap-
proach to sequencing based on hydrogen ion release when a
nucleotide is incorporated into a DNA strand by polymerase
(Table 8)[ 41]. An ion sensor can detect hydrogen ions and
convert this ion chemical signal to digital sequence informa-
tion eliminating the need of optical reading at each dNTP
incorporation.
Other third-generation platforms under development
make use of nanophotonic visualization chamber, ion semi-
conductor, electron microscopy, a variety of nanotech-
nologies like nanopores (Oxford Nanopore Technologies),
nanochannels (BioNanomatrix/nanoAnalyzer), nanoparti-
cles (GE Global Research), nanoballs (Complete Genomics),
nanowells (CrackerBio), nanoknifes (Renveo), and specially
engineered sensor DNA polymerase (VisiGen Biotechnolo-
gies) [42]. They promise even larger and faster data pro-
duction although they are still under development and a
few years away from commercial use. In principle also DNA
microarrays could allow sequencing by hybridization using
ultrafast nonenzymatic methods (Genizon BioSciences) and
somebody even suggests that mass spectrometry might be
used to determine mass diﬀerences between DNA fragments
produced by chain termination [43].
The beginning of several individual genome projects has
gradually decreased the cost of sequencing an individual
genome, and it is likely that the $1,000 cost per person will
be reached in few years. In medicine, the “personal genome”
agemadepossiblebyNGSwillbeanimportantmilestonefor
the entire genomic ﬁeld and will mark a transition from sin-
g l eg e n et e s t i n gt ow h o l eg e n o m ee v a l u a t i o n[ 44].
It is impossible to predict today which NGS will eventu-
a l l yd o m i n a t eg e n o m i cr e s e a r c h ,b u ti ti ss u r et h a tc o s tr e -
ductions, sequencing speed, and better accuracy will make
NGS an essential molecular tool in several areas of biology
and medicine.
Althoughthecostofwholegenomesequencinghasdrop-
ped signiﬁcantly, it remains a major obstacle since it can
reach $100,000 for a single individual. However, targeting
sequencing of speciﬁc regions of interest can decrease the
overall cost and improve eﬃciency of NGS making this
technology ready for diagnostic use [45].
Also the ﬁeld of epilepsy is potentially aﬀected by NGS.
Indeed too many genes and genetic conditions can be as-
sociated with epilepsy to make impossible for the clinicians a
general use of speciﬁc monogene test for the vast majority of
nonsyndromic or idiopathic epileptic patients. NGS is cha-
nging this situation by targeting several genome regions
where known epilepsy genes are located and using enrich-
ment techniques to signiﬁcantly reduce the cost and improve
eﬃciency. Targeted sequencing usually tests all protein-cod-
ing exons (functional exosome) which only requires roughly
5% as much sequencing than whole genome. This strategy
will reduces the cost to about $3,000 or even less per sin-
gleindividual.Targetedselectiontechnologieshavebeenma-
rketedandsuccessfullyusedindiﬀerentNGSprojectsandare
becoming the tool of choice in several conditions, including
epilepsy [46].
4.Targeting SequencingandEpilepsy
GenePanels
Adiagnosticpanelisthecontemporaneoustargetedsequenc-
ing of a number of known genes that have already been
identiﬁed as cause of a particular disease. A diagnostic panel
is very diﬀerent from whole genome or exome sequencing.
Only genes clearly associated with a disease are examined.
The genes included in the panel can be decided by the
prescribingphysicianorbyadhoccommitteesofexpertsthat
can reach a consensus on the number and type of genes to
test making commercially available diagnostic panel kits for
speciﬁc diseases. This strategy should make easier to detect
genetic variants that after validation by Sanger sequencing
can be interpreted as the cause of the disease. Of course
diagnostic panels and targeted sequencing make sense only
if the condition is caused by several or very large number of
genes. Many genetic disorders fall in this condition and are
excellent candidate for the development of diagnostic panels.
Epilepsy is an excellent example of such situation since it is a
relative frequent disease aﬀecting 1% of the population in a
variety of forms, at diﬀerent ages, with diﬀerent progression.
A genetic cause of epilepsy can be reasonably supposed in
sporadic cases if trauma, tumor, or infection can be ruled
out. In such circumstance all genetic information about
epilepsy genes identiﬁed over the years in familial cases canNeurology Research International 13
Table 7: Other inherited errors of metabolism with epilepsy.
Gene symbol Defective enzyme name Disease
(a) Congenital Disorder of Glycosylation (CDG) (23 genes)
ALG1 N-linked glycosylation 1, beta-1,4-mannosyltransferase homolog CDG
ALG2 N-linked glycosylation 2, alpha-1,3-mannosyltransferase homolog CDG
ALG3 N-linked glycosylation 3, alpha-1,3-mannosyltransferase homolog CDG
ALG6 N-linked glycosylation 6, alpha-1,3-glucosyltransferase homolog CDG
ALG8 N-linked glycosylation 8, alpha-1,3-glucosyltransferase homolog CDG
ALG9 N-linked glycosylation 9, alpha-1,3-glucosyltransferase homolog CDG
ALG12 N-linked glycosylation 12, alpha-1,3-glucosyltransferase homolog CDG
B4GALT1 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 1 CDG
COG1 Component of oligomeric golgi complex 1 CDG
COG7 Component of oligomeric golgi complex 7 CDG
COG8 Component of oligomeric golgi complex 8 CDG
DOLK Dolichol kinase CDG
DPAGT1 Dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetyl
glucosamine phosphotransferase 1 (GlcNAc-1-P transferase) CDG
DPM1 Dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic subunit CDG
DPM3 Dolichyl-phosphate mannosyltransferase polypeptide 3 CDG
MOGS Mannosyl-oligosaccharide glucosidase CDG
MGAT2 Mannosyl (alpha-1,6-)-glycoprotein
beta-1,2-N-acetylglucosaminyltransferase CDG
MPDU1 Mannose-P-dolichol utilization defect 1 CDG
MPI Mannose phosphate isomerase CDG
PMM2 Phosphomannomutase 2 CDG
RFT1 Requiring ﬁfty three 1 homolog CDG
SLC35A1 Solute carrier family 35 (CMP-sialic acid transporter), member A1 CDG
SLC35C1 Solute carrier family 35, member C1 CDG
(b) Neuronal ceroid lipofuscinosis (NCL) (8 genes)
CLN3 Ceroid-lipofuscinosis, neuronal 3 NLC
CLN5 Ceroid-lipofuscinosis, neuronal 5 NLC
CLN6 Ceroid-lipofuscinosis, neuronal 6 NLC
CLN8 Ceroid-lipofuscinosis, neuronal 8 NLC
CTSD Cathepsin D NLC
MFSD8 Major facilitator superfamily domain containing 8 NLC
PPT1 Palmitoyl-protein thioesterase 1 NLC
TPP1 Tripeptidyl peptidase I NLC
(c) Defects of mitochondrial metabolism including coenzyme Q deﬁciency (35 genes)
APTX Aprataxin Coenzyme Q10 Deﬁciency
ATPAF2 ATP synthase mitochondrial F1 complex assembly factor 2 ATPase deﬁciency
BCS1L BCS1-like Leigh syndrome
C12ORF65 Chromosome 12 open reading frame 65 Leigh syndrome
C8ORF38 Chromosome 8 open reading frame 38 Leigh syndrome
CABC1 Chaperone activity of bc1 complex-like, mitochondria Coenzyme Q10 deﬁciency
COQ2 Coenzyme Q2 homolog, prenyltransferase (yeast) Coenzyme Q10 deﬁciency
COQ9 Coenzyme Q9 homolog (S. cerevisiae) Coenzyme Q10 deﬁciency
COX10 COX10 homolog, cytochrome c oxidase assembly protein, heme A:
farnesyltransferase (yeast) Leigh syndromeCOX1014 Neurology Research International
Table 7: Continued.
Gene symbol Defective enzyme name Disease
COX15 COX15 homolog, cytochrome c oxidase assembly protein (yeast) Leigh syndrome
DLD Dihydrolipoamide dehydrogenase Leigh syndrome
GCSH Glycine cleavage system protein H (aminomethyl carrier) Glycine encephalopathy
GCST Aminomethyltransferase (glycine cleavage system protein T) Glycine encephalopathy
GLDC Glycine dehydrogenase (decarboxylating) Glycine encephalopathy
HSD17B10 Hydroxysteroid (17-beta) dehydrogenase 10 HSD17B10 deﬁciency
LRPPRC Leucine-rich PPR-motif containing Leigh syndrome
NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2,8kDa Leigh syndrome
NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa Leigh syndrome
NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa Leigh syndrome
NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa Leigh syndrome
NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa Leigh syndrome
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa Leigh syndrome
NDUFV1 NADH dehydrogenase (ubiquinone) ﬂavoprotein 1, 51kDa Leigh syndrome
PC Pyruvate carboxylase Leigh syndrome
PDHA1 Pyruvate dehydrogenase (lipoamide) alpha 1 Leigh syndrome
PDSS1 Prenyl (decaprenyl) diphosphate synthase, subunit 1 Coenzyme Q10 deﬁciency
PDSS2 Prenyl (decaprenyl) diphosphate synthase, subunit 2 Coenzyme Q10 deﬁciency]
POLG Polymerase (DNA directed), gamma Mitochondrial DNA
depletion Syndrome
RARS2 Arginyl-tRNA synthetase 2, mitochondrial Pontocerebellar hypoplasia
SCO2 SCO cytochrome oxidase deﬁcient homolog 2 (yeast) Leigh syndrome
SDHA Succinate dehydrogenase complex, subunit A, ﬂavoprotein (Fp) Leigh syndrome
SURF1 Surfeit 1 Leigh syndrome
TACO1 Translational activator of mitochondrially encoded cytochrome c oxidase I Leigh syndrome
TMEM70 Transmembrane protein 70 Encephalocardiomyopathy
VDAC1 voltage-dependent anion channel 1 VDAC deﬁciency
(d) Mucopolysaccharidosis (MPS) and mucolipidosis (MLP) (15 genes)
ARSB Arylsulfatase B M P S6( M a r o t e a u x - L a m y
syndrome)
GALNS Galactosamine (N-acetyl)-6-sulfate sulfatase MPS 4A (Morquio
syndrome)
GLB1 Galactosidase, beta 1 GM1-gangliosidosis
GNPTAB N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits Mucolipidosi 2 (I cell
disease) and 3A
GNPTG N-acetylglucosamine-1-phosphate transferase, gamma subunit Mucolipidosi 3C
GNS Glucosamine (N-acetyl)-6-sulfatase MPS 3D (Sanﬁlippo D
syndrome)
GUSB Glucuronidase, beta MPS 7 (Sly syndrome)
HGSNAT Heparan-alpha-glucosaminide N-acetyltransferase MPS 3C (Sanﬁlippo C
syndrome)
HYAL1 Hyaluronoglucosaminidase 1 MPS 9
IDS Iduronate 2-sulfatase MPS 2 (Hunter syndrome)
IDUA Iduronidase, alpha-L- MPS 1H (Hurler
syndrome)
MCOLN1 Nucolipin 1 Mucolipidosi 4
NAGLU N-acetylglucosaminidase, alpha MPS 3B (Sanﬁlippo B
syndrome)
SGSH N-sulfoglucosamine sulfohydrolase MPS 3A (Sanﬁlippo A
syndrome)
SUMF1 Sulfatase modifying factor 1 Multiple sulfatase
deﬁciencyNeurology Research International 15
Table 7: Continued.
Gene symbol Defective enzyme name Disease
(e) Peroxisome biogenesis disorders (PBD) (9 genes): Zellweger syndrome (ZWS): neonatal
adrenoleukodystrophy (NALD): infantile refsum disease (IRD): rhizomelic chondrodysplasia punctata type 1 (RCDP1)
PEX1 Peroxisomal biogenesis factor 1 ZWS-NADL-IRD
PEX2 Peroxisomal biogenesis factor 2 ZWS-IRD
PEX3 Peroxisomal biogenesis factor 3 ZWS
PEX5 Peroxisomal biogenesis factor 5 ZWS-NADL
PEX6 Peroxisomal biogenesis factor 6 ZWS
PEX7 Peroxisomal biogenesis factor 7 RCDP1
PEX12 Peroxisomal biogenesis factor 12 ZWS
PEX14 Peroxisomal biogenesis factor 14 ZWS
PEX26 Peroxisomal biogenesis factor 26 ZWS-NADL-IRD
Table 8: Comparison of commercially available sequencing platforms.
(a) Massive parallel clonal ampliﬁcation with optical detection
Roche 454 Life Technologies SOLiD Illumina
Library ampliﬁcation emPCR∗ emPCR∗ On glass
Sequencing Incorporation of unlabeled dNTPs Ligase-mediated addition of
ﬂuorescent oligoNTPs (2bp)
Incorporation of end-blocked
ﬂuorescent dNTPs
Detection Light emission from release of PPi Fluorescence emission from ligated
dye-labeled oligoNTPs
Fluorescence emission from
incorporated labeled oligoNTPs
Progression Unlabeled dNTPS added in
base-speciﬁc fashion
Chemical cleavage removes dye and
oligoNTP
Chemical cleavage ﬂuorescent dye
and blocking group
Errors Insertion/deletion End of read End of read
Length 400bp 75bp 150bp
Overall yield/run 500Mbp >100Gbp 200Gbp
(b) Fluorescent and semiconductor single molecule sequencing
Helicos Paciﬁc biosystem Iontorrent
Library ampliﬁcation N/A-tSMS∗∗ N/A-SMRT∗∗∗ sequencing Optional PCR
Sequencing Incorporation of ﬂuorescent labeled
dNTPs
Polymerase incorporation terminal
phosphate labeled dNTPs
Polymerase incorporation of dNTPs
releases H+
Detection Laser-induced emission from
incorporated dNTP
Real time detection of ﬂuorescent
d y ei np o l y m e r a s ea c t i v es i t e
Semiconductor ion sensor detects
H+ released during dNTPs
incorporation
Progression Chemical cleavage of dNTP
ﬂuorescent group
N/A ﬂuorescent dyes are removed as
PPi with dNTPs incorporation
H+ signal during each dNTP
incorporation is converted in
voltage signal
Errors Insertion/deletion Insertion/deletion Insertion/deletion
Length 35bp 1000bp 200–400bp
Overall yield/run 21–37Gbp >100Gbp 1Gbp
∗emPCR (emulsion PCR) is an ampliﬁcation method where DNA library fragments are mixed with beads and PCR reagents in an oil emulsion that allows
massive ampliﬁcation of bead-DNA in a single reaction.
∗∗tSMS: true Single Molecule Sequencing.
∗∗∗SMRT (Single Molecule Real Time)
bp: base pair, Mbp: Mega base pair (106 bp), Gbp: Giga base pair (109 bp), dNTP: deoxynucleotide-tri-phosphate, PPi: pyrophosphate.
be used to identify the causative gene through an epilepsy
diagnostic panel. Indeed in the case of epilepsy the identiﬁed
genes are so many that they can be classiﬁed in subpanels
of genes that underline a common clinical entity (Table 9).
Clinical considerations may suggest the clinician to include
inadiagnostic panel othergenesorgenesfromdiﬀerent sub-
panels. At the present the ﬁrst diagnostic panels for epilepsy
that can analyze up to 400 diﬀerent genes (CeGaT GmbH)
are commercially available [47].
5. FuturePerspectivesand Conclusions
The genetics of epilepsy has evolved from ion channel and
neurotransmitter receptor subunits to newly discovered16 Neurology Research International
Table 9: Epilepsy diagnostic panels.
Subpanels With Homogeneous Clinical Entities Table Number of genes
Myoclonic epilepsy, febrile seizures, absences 1 37
Encephalopathies 3 30
X-linked mental retardation (XLMR) 4(a) 25
Joubert syndrome 4(b) 10
Lissencephaly and polymicrogyria 4(c) 18
Severe Microcephaly and pontocerebellar hypoplasia 4(d) 22
Walker-Warburg syndrome 4(e) 6
Holoprosencephaly 4(f) 8
Leukodystrophies 5(a) 20
Migraine 5(b) 6
Disorders of the Ras-MAPK pathway 5(c) 13
Hyperekplexia for defective glycine neurotransmission 5(d) 5
Neuronal migration disorders 5(e) 31
Inherited errors of metabolism 6 49
Congenital disorder of glycosylation (CDG) 7(a) 23
Neuronal ceroid lipofuscinosis (NCL) 7(b) 8
Defects of mitochondrial metabolism including coenzyme Q deﬁciency 7(c) 35
Mucopolisaccaridosis and mucolipidosis 7(d) 15
Peroxisome biogenesis disorders (PBD) 7(e) 9
Syndromic epilepsy 2 47
genes highlighting the importance of diﬀerent pathways in
the epileptogenesis. Furthermore, it has been demonstrated
that copy number variations collectively explain a larger
portion of idiopathic epilepsy than any single gene. These
studies have identiﬁed structural genomic variations asso-
ciated with idiopathic epilepsy, representing a change from
the conventional knowledge that chromosome microarray
analysis is useful only for patients with intellectual disability
or dysmorphism [48]. Genetic testing techniques are rapidly
evolving and whole exome or whole genome sequencing,
performing at increasingly cheaper costs, will allow rapid
discovery of other pathogenic mutations, variants in non-
coding DNA, and copy number variations encompassing
several genes. This rapidly accumulating genetic information
will expand our understanding of epilepsy, and will allow
more rational and eﬀective treatment. However, along with
the ability to identify genetic variants potentially associated
with epilepsy it is imperative to validate genetic associations
and analyze their clinical signiﬁcance.
Is it worth? The main objective of a diagnostic panel for
epilepsy is to discover the molecular defect in all possible
cases to create a speciﬁc and personalized treatment of the
disease than can be pharmacologically diﬀerent for diﬀerent
types of molecular defects. Personalized therapy will be pos-
sibleonlywithinagenomicmedicine.Butgenomicmedicine
at the same time will raise other questions: what to do if
more than one genetic variant is identiﬁed in the same epi-
leptic patient? Can we understand how genetic interactions
will modulate the disease severity and prognosis? Can in-
teraction of speciﬁc genetic variants and environmental fa-
ctors modulate the clinical spectrum of the disorder? What
to do if the diagnostic panel is inconclusive? Are the costs
aﬀordable?Theseareonlyfewquestionsthatthegenomicsof
epilepsy will raise. The answers will require time, a lot
of sequencing, and probably the development of new and
cheaper sequencing technologies.
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